Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats

Minoru Watanabe, Tomonori Tateishi, Masako Asoh, Hironori Nakura, Masami Tanaka, Toshio Kumai, Shinichi Kobayashi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Haloperidol (HP), an antipsychotic drug, is N-dealkylated by cytochrome P450 (CYP) to 4-fluorobenzoylpropionic acid (FBPA). The purpose of this study was to identify whether CYP3A metabolizes HP to FBPA in hepatic microsomes of rats and to investigate whether an inhibitor or an inducer of CYP3A affects HP pharmacokinetics in rats. The rate of FBPA formation was determined in hepatic microsomes from 8-week-old male Sprague-Dawley rats. Among several specific CYP isozyme inhibitors including troleandomycin (TAO), diethyldithiocarbamate, furafylline and quinine, only TAO showed marked inhibition of FBPA formation. Anti-rat CYP3A serum inhibited FBPA formation by 76.4%, while other anti-rat CYP sera (1A1, 1A2, 2B1, 2C11, 2E1) only slightly did. In a pharmacokinetic study, 8-weekold male Sprague-Dawley rats were given 0.5 mg/kg HP intravenously after treatment with 100 mg/kg erythromycin, a CYP3A inhibitor, or 80 mg/kg dexamethasone, a CYP3A inducer, intraperitoneally once a day for 7 days or 2 days, respectively or untreated. HP half-life was prolongated to 171% of the average control value by erythromycin and shortened to 49% of control by dexamethasone. HP clearance was reduced to 63% of control by erythromycin and was increased to 167% of control by dexamethasone. These results suggested that CYP3A mainly catalyzed HP to FBPA in rats, and the modification of this enzyme activity would affect the pharmacokinetics of HP.

Original languageEnglish
Pages (from-to)337-342
Number of pages6
JournalFundamental and Clinical Pharmacology
Volume13
Issue number3
Publication statusPublished - 1999
Externally publishedYes

Fingerprint

Dealkylation
Cytochrome P-450 CYP3A
Haloperidol
Pharmacokinetics
Acids
Erythromycin
Troleandomycin
Cytochrome P-450 Enzyme System
Dexamethasone
Microsomes
Sprague Dawley Rats
Ditiocarb
Quinine
Liver
Serum
Antipsychotic Agents
Isoenzymes
Half-Life

Keywords

  • CYP3A
  • Dexamethasone
  • Erythromycin
  • Haloperidol
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Watanabe, M., Tateishi, T., Asoh, M., Nakura, H., Tanaka, M., Kumai, T., & Kobayashi, S. (1999). Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats. Fundamental and Clinical Pharmacology, 13(3), 337-342.

Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats. / Watanabe, Minoru; Tateishi, Tomonori; Asoh, Masako; Nakura, Hironori; Tanaka, Masami; Kumai, Toshio; Kobayashi, Shinichi.

In: Fundamental and Clinical Pharmacology, Vol. 13, No. 3, 1999, p. 337-342.

Research output: Contribution to journalArticle

Watanabe, M, Tateishi, T, Asoh, M, Nakura, H, Tanaka, M, Kumai, T & Kobayashi, S 1999, 'Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats', Fundamental and Clinical Pharmacology, vol. 13, no. 3, pp. 337-342.
Watanabe M, Tateishi T, Asoh M, Nakura H, Tanaka M, Kumai T et al. Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats. Fundamental and Clinical Pharmacology. 1999;13(3):337-342.
Watanabe, Minoru ; Tateishi, Tomonori ; Asoh, Masako ; Nakura, Hironori ; Tanaka, Masami ; Kumai, Toshio ; Kobayashi, Shinichi. / Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats. In: Fundamental and Clinical Pharmacology. 1999 ; Vol. 13, No. 3. pp. 337-342.
@article{f85eeed52db249608de27a6d3c68b4d8,
title = "Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats",
abstract = "Haloperidol (HP), an antipsychotic drug, is N-dealkylated by cytochrome P450 (CYP) to 4-fluorobenzoylpropionic acid (FBPA). The purpose of this study was to identify whether CYP3A metabolizes HP to FBPA in hepatic microsomes of rats and to investigate whether an inhibitor or an inducer of CYP3A affects HP pharmacokinetics in rats. The rate of FBPA formation was determined in hepatic microsomes from 8-week-old male Sprague-Dawley rats. Among several specific CYP isozyme inhibitors including troleandomycin (TAO), diethyldithiocarbamate, furafylline and quinine, only TAO showed marked inhibition of FBPA formation. Anti-rat CYP3A serum inhibited FBPA formation by 76.4{\%}, while other anti-rat CYP sera (1A1, 1A2, 2B1, 2C11, 2E1) only slightly did. In a pharmacokinetic study, 8-weekold male Sprague-Dawley rats were given 0.5 mg/kg HP intravenously after treatment with 100 mg/kg erythromycin, a CYP3A inhibitor, or 80 mg/kg dexamethasone, a CYP3A inducer, intraperitoneally once a day for 7 days or 2 days, respectively or untreated. HP half-life was prolongated to 171{\%} of the average control value by erythromycin and shortened to 49{\%} of control by dexamethasone. HP clearance was reduced to 63{\%} of control by erythromycin and was increased to 167{\%} of control by dexamethasone. These results suggested that CYP3A mainly catalyzed HP to FBPA in rats, and the modification of this enzyme activity would affect the pharmacokinetics of HP.",
keywords = "CYP3A, Dexamethasone, Erythromycin, Haloperidol, Pharmacokinetics",
author = "Minoru Watanabe and Tomonori Tateishi and Masako Asoh and Hironori Nakura and Masami Tanaka and Toshio Kumai and Shinichi Kobayashi",
year = "1999",
language = "English",
volume = "13",
pages = "337--342",
journal = "Fundamental and Clinical Pharmacology",
issn = "0767-3981",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Role of CYP3A in haloperidol N-dealkylation and pharmacokinetics in rats

AU - Watanabe, Minoru

AU - Tateishi, Tomonori

AU - Asoh, Masako

AU - Nakura, Hironori

AU - Tanaka, Masami

AU - Kumai, Toshio

AU - Kobayashi, Shinichi

PY - 1999

Y1 - 1999

N2 - Haloperidol (HP), an antipsychotic drug, is N-dealkylated by cytochrome P450 (CYP) to 4-fluorobenzoylpropionic acid (FBPA). The purpose of this study was to identify whether CYP3A metabolizes HP to FBPA in hepatic microsomes of rats and to investigate whether an inhibitor or an inducer of CYP3A affects HP pharmacokinetics in rats. The rate of FBPA formation was determined in hepatic microsomes from 8-week-old male Sprague-Dawley rats. Among several specific CYP isozyme inhibitors including troleandomycin (TAO), diethyldithiocarbamate, furafylline and quinine, only TAO showed marked inhibition of FBPA formation. Anti-rat CYP3A serum inhibited FBPA formation by 76.4%, while other anti-rat CYP sera (1A1, 1A2, 2B1, 2C11, 2E1) only slightly did. In a pharmacokinetic study, 8-weekold male Sprague-Dawley rats were given 0.5 mg/kg HP intravenously after treatment with 100 mg/kg erythromycin, a CYP3A inhibitor, or 80 mg/kg dexamethasone, a CYP3A inducer, intraperitoneally once a day for 7 days or 2 days, respectively or untreated. HP half-life was prolongated to 171% of the average control value by erythromycin and shortened to 49% of control by dexamethasone. HP clearance was reduced to 63% of control by erythromycin and was increased to 167% of control by dexamethasone. These results suggested that CYP3A mainly catalyzed HP to FBPA in rats, and the modification of this enzyme activity would affect the pharmacokinetics of HP.

AB - Haloperidol (HP), an antipsychotic drug, is N-dealkylated by cytochrome P450 (CYP) to 4-fluorobenzoylpropionic acid (FBPA). The purpose of this study was to identify whether CYP3A metabolizes HP to FBPA in hepatic microsomes of rats and to investigate whether an inhibitor or an inducer of CYP3A affects HP pharmacokinetics in rats. The rate of FBPA formation was determined in hepatic microsomes from 8-week-old male Sprague-Dawley rats. Among several specific CYP isozyme inhibitors including troleandomycin (TAO), diethyldithiocarbamate, furafylline and quinine, only TAO showed marked inhibition of FBPA formation. Anti-rat CYP3A serum inhibited FBPA formation by 76.4%, while other anti-rat CYP sera (1A1, 1A2, 2B1, 2C11, 2E1) only slightly did. In a pharmacokinetic study, 8-weekold male Sprague-Dawley rats were given 0.5 mg/kg HP intravenously after treatment with 100 mg/kg erythromycin, a CYP3A inhibitor, or 80 mg/kg dexamethasone, a CYP3A inducer, intraperitoneally once a day for 7 days or 2 days, respectively or untreated. HP half-life was prolongated to 171% of the average control value by erythromycin and shortened to 49% of control by dexamethasone. HP clearance was reduced to 63% of control by erythromycin and was increased to 167% of control by dexamethasone. These results suggested that CYP3A mainly catalyzed HP to FBPA in rats, and the modification of this enzyme activity would affect the pharmacokinetics of HP.

KW - CYP3A

KW - Dexamethasone

KW - Erythromycin

KW - Haloperidol

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=0033279819&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033279819&partnerID=8YFLogxK

M3 - Article

C2 - 10392310

AN - SCOPUS:0033279819

VL - 13

SP - 337

EP - 342

JO - Fundamental and Clinical Pharmacology

JF - Fundamental and Clinical Pharmacology

SN - 0767-3981

IS - 3

ER -